
The Human Clustered Protocadherin Genes Provide a Single Cell Identity Code for Neural Circuit Assembly
Description
The human clustered protocadherin (Pcdh) genes are encoded by three tandem gene clusters (a, b & g) spanning nearly 1 million base pairs of DNA chromosome 5 (5q31). The function of the Pcdh gene cluster is to provide a cell surface “identity code” for individual neurons, which is required for normal neural circuit assembly. This code is generated through a mechanism of stochastic promoter choice and RNA splicing, which generates a combination of distinct protein isoforms that form random cis-dimers at the interface between apposing cell membranes. Stochastic promoter activation occurs through a remarkable mechanism that involves the activation of an anti-sense promoter within the exon of each protein isoform that generates a long non-coding lncRNA that reads through the upstream antisense promoter. This in turn leads to the demethylation of the sense strand promoter, the binding of CTCF/cohesin to both the sense and antisense promoters and to two binding sites in a distal enhancer located over 300Kb away. DNA looping brings the enhancer and promoter together to establish a epigenetically stable promoter choice. Once generated, the cell surface code is “read” through highly specific homophilic interactions between cis-dimers at the interface between apposing membranes. These interactions lead to the formation of a protein lattice between cells as revealed by Cryoelectron tomography. Importantly, this homophilic binding results in repulsion rather that adhesion, thus providing individual neurons the ability to distinguish between self and non-self and to avoid self. Studies of Pcdh gene cluster deletions in mice reveal neuron-type specific defects in neurite self-avoidance and tiling, and behavioral abnormalities. In humans, genetic studies reveal DNA sequence variants that associate with the Pcdh gene cluster in autism, schizophrenia and bipolar disease.
Speaker Bio
Tom Maniatis is a graduate of the University of Colorado, Boulder, he received his PhD in Molecular Biology from Vanderbilt University, and carried out postdoctoral studies in the laboratories of Dr. Mark Ptashne at Harvard and Fred Sanger at the MRC laboratory of Molecular Biology in Cambridge England. He has held faculty positions at Harvard University, Cold Spring Harbor Laboratory, the California Institute of Technology and is currently on the faculty at Columbia. He is known for the development and application of recombinant DNA methods to studies of the molecular mechanisms of transcription regulation, RNA splicing and signal transduction. Tom’s current research interests are in molecular neuroscience, with a focus on the regulation of gene expression in neural circuit development, and in the molecular mechanisms that underlie the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS). He is a member of the US National Academies of Science and Medicine, and has received the Lasker Koshland Lifetime Achievement Award among other honors in recognition of his research contributions.